Related Experiment Video
Updated: Jul 17, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Ameliorative effect of Chlorophytum borivilianum root on lipid metabolism in hyperlipaemic rats
N P Visavadiya1, A V R L Narasimhacharya
1Department of Biosciences, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India.
Abstract:
1. The present study examined the efficacy of Chlorophytum borivilianum root (powder) in modulating the hyperlipaemic/hypercholesteraemic conditions in male albino rats. 2. Administration of C. borivilianum (0.75 and 1.5 g root powder/rat per day for 4 weeks) to hypercholesteraemic rats significantly increased high-density lipoprotein-cholesterol levels and decreased plasma and hepatic lipid profiles. 3. In addition, there were significant increases in faecal cholesterol, neutral sterol and bile acid excretion with elevated hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and bile acid production. 4. Furthermore, the hypercholesteraemic rats treated with both doses of C. borivilianum also exhibited increases in superoxide dismutase and ascorbic acid levels. 5. Normocholesteraemic animals treated with both doses of C. borivilianum root powder did not show any significant variation in either lipid or anti-oxidant profiles, except for an increase in the hepatic ascorbic acid concentration compared with their untreated counterparts. 6. The hypolipaemic/hypocholesteraemic effect of C. borivilianum root powder appears to be mediated by an increase in cholesterol turnover via increased faecal cholesterol excretion and, second, through an endogenous cholesterol conversion into bile acid. 7. Administration of C. borivilianum root powder also increased the activities of anti-oxidant enzymes and vitamin C levels, which may have enhanced the anti-oxidant capacity of the liver.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis III: Management